1. Home
  2. ASLE vs AKBA Comparison

ASLE vs AKBA Comparison

Compare ASLE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

N/A

Current Price

$4.60

Market Cap

242.5M

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.39

Market Cap

248.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASLE
AKBA
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.5M
248.3M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
ASLE
AKBA
Price
$4.60
$0.39
Analyst Decision
Hold
Buy
Analyst Count
2
6
Target Price
★ $6.50
$3.92
AVG Volume (30 Days)
392.3K
★ 8.6M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
★ 93.94
EPS
N/A
★ N/A
Revenue
★ $335,286,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.68
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.54
$0.54
52 Week High
$7.93
$1.89

Technical Indicators

Market Signals
Indicator
ASLE
AKBA
Relative Strength Index (RSI) 38.95 25.15
Support Level $4.54 N/A
Resistance Level $5.14 $1.54
Average True Range (ATR) 0.18 0.07
MACD 0.03 -0.01
Stochastic Oscillator 17.31 9.73

Price Performance

Historical Comparison
ASLE
AKBA

About ASLE AerSale Corporation

AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: